NCT06182735

CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma

A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-NKT in the Treatment of Relapsed or Metastatic Advanced Renal Cell Carcinoma.

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a phase I, open-label, single-arm study conducted to evaluate the safety, tolerability, PK, and preliminary efficacy of CGC729 with Relapsed or Metastatic advanced renal cell carcinoma. Condition or disease:Renal Cell Carcinoma Intervention/treatment: Biological: CD70 CAR-NKT cells Phase 1

Detailed description

Dose exploration for this study will be a 3+3 design with a target DLT rate of \<1/3. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD. Dose exploration can be discontinued once one or more dose levels with an acceptable safety profile and satisfactory antitumor activity have been selected for subsequent evaluation. During the treatment period of the study, three dose levels of CGC729 will be evaluated. Each of the dose levels will evaluate the safety of the CAR-NKT cells.

Conditions

• Renal Cell Carcinoma

Interventions

Type	Name	Description
COMBINATION_PRODUCT	Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells	Biological: CD70 CAR-NKT cells. Drug: Cyclophosphamide. Drug: Fludarabine.

Timeline

• Start date: 2023-07-17
• Primary completion: 2025-01-28
• Completion: 2025-01-28
• First posted: 2023-12-27
• Last updated: 2023-12-27

Locations

1 site across 1 country: China